MFG
VRTX icon

Mendota Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Mendota Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20
Closed -$7.83K – 113
2025
Q3 		$7.83K Hold
20
– – 0.01% 103
2025
Q2 		$8.9K Hold
20
– – 0.01% 79
2025
Q1 		$9.7K Hold
20
– – 0.01% 80
2024
Q4 		$8.05K Sell
20
-21
-51% -$9.73K 0.01% 247
2024
Q3 		$19.1K Sell
41
-39
-49% -$18.7K 0.01% 215
2024
Q2 		$37.5K Hold
80
– – 0.02% 189
2024
Q1 		$33.4K Sell
80
-41
-34% -$17.3K 0.02% 193
2023
Q4 		$49.2K Buy
+121
New +$44.7K 0.04% 202

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Mendota Financial Group's VRTX Position: Q4 2025 in Review

Mendota Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 20 shares — an estimated $7.83K sold.

Mendota Financial Group first reported a position in VRTX in Q4 2023 and held it in 8 quarters. The position peaked at $49.2K in Q4 2023. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Mendota Financial Group reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mendota Financial Group sold 20 Vertex Pharmaceuticals shares in Q4 2025, an estimated $7.83K.
  • Mendota Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Mendota Financial Group's Vertex Pharmaceuticals position peaked at $49.2K in Q4 2023.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Mendota Financial Group's 13F filing for Q4 2025, filed 20 Jan 2026.